ValoreQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25TTMFlussi di cassa derivanti dalle attività di investimento-539 M730 M564 M700 M-48 M1.95 BLiquidità derivante dalle attività di finanziamento-3 M4 M9 M-1 M581 M593 MLiquidità libera303 M-1.16 B-922 M-880 M891 M-2.08 B
Moderna Inc
Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".
The company's commercial products are the Moderna COVID-19 vaccine, marketed as Spikevax and a respiratory syncytial virus vaccine, marketed as Mresvia. The company has 44 treatment and vaccine candidates, of which 37 have entered clinical trials. Candidates include possible vaccines for influenza, HIV, Epstein–Barr virus, the Nipah virus, chikungunya, human metapneumovirus, varicella zoster virus, as well as a cytomegalovirus vaccine, a Zika virus vaccine funded by the Biomedical Advanced Research and Development Authority, and three cancer vaccines.